AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced an expansion of its accessibility program for inhaled respiratory drugs in the US. The initiative will cap monthly expenses at USD 35 for eligible patients suffering from asthma and chronic obstructive pulmonary disease (COPD). The savings program includes coverage for Airsupra (albuterol + budesonide), Bevespi Aerosphere (glycopyrrolate + formoterol fumarate), Breztri Aerosphere (budesonide + glycopyrrolate + formoterol fumarate), and Symbicort (budesonide + formoterol fumarate dihydrate).
This new patient assistance initiative builds upon AstraZeneca’s reduction in the list price of Symbicort, which was announced in January of this year. The company’s commitment to affordability and accessibility underscores its dedication to improving the lives of patients with respiratory conditions by reducing the financial burden of their treatments.
The expansion of the program is expected to make a significant difference for patients who rely on these essential medications, potentially increasing adherence to treatment regimens and improving health outcomes.- Flcube.com
